{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T14:57:53Z","timestamp":1788793073506,"version":"build-2803163510"},"reference-count":112,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T00:00:00Z","timestamp":1712620800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T00:00:00Z","timestamp":1712620800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82204541"],"award-info":[{"award-number":["82204541"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81972719"],"award-info":[{"award-number":["81972719"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"crossref","award":["BK20210913"],"award-info":[{"award-number":["BK20210913"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"crossref","award":["BK20220671"],"award-info":[{"award-number":["BK20220671"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"crossref","award":["BK20201012"],"award-info":[{"award-number":["BK20201012"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"crossref","award":["BK20210910"],"award-info":[{"award-number":["BK20210910"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"crossref"}]},{"name":"National science research in Universities of Jiangsu Province","award":["22KJB320009"],"award-info":[{"award-number":["22KJB320009"]}]},{"name":"National science research in Universities of Jiangsu Province","award":["21KJA320008"],"award-info":[{"award-number":["21KJA320008"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Metastasis Rev"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1007\/s10555-024-10185-8","type":"journal-article","created":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T06:01:31Z","timestamp":1712642491000},"page":"1075-1093","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["In vivo manufacture and manipulation of CAR-T cells for better druggability"],"prefix":"10.1007","volume":"43","author":[{"given":"Rui","family":"Hou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sijin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhangchun","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiang","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junnian","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,9]]},"reference":[{"key":"10185_CR1","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.drudis.2016.11.021","volume":"22","author":"Applications and perspectives","year":"2017","unstructured":"Abi Hussein, H., et al. (2017). Global vision of druggability issues. Drug Discovery Today, 22, 404\u2013415. https:\/\/doi.org\/10.1016\/j.drudis.2016.11.021","journal-title":"Drug Discovery Today"},{"key":"10185_CR2","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.cbpa.2011.05.020","volume":"15","author":"EB Fauman","year":"2011","unstructured":"Fauman, E. B., Rai, B. K., & Huang, E. S. (2011). Structure-based druggability assessment\u2013Identifying suitable targets for small molecule therapeutics. Current opinion in Chemical Biology, 15, 463\u2013468. https:\/\/doi.org\/10.1016\/j.cbpa.2011.05.020","journal-title":"Current opinion in Chemical Biology"},{"key":"10185_CR3","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1038\/nrd2275","volume":"6","author":"J Owens","year":"2007","unstructured":"Owens, J. (2007). Determining druggability. Nature Reviews Drug Discovery, 6, 187. https:\/\/doi.org\/10.1038\/nrd2275","journal-title":"Nature Reviews Drug Discovery"},{"key":"10185_CR4","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/nbt1273","volume":"25","author":"AC Cheng","year":"2007","unstructured":"Cheng, A. C., et al. (2007). Structure-based maximal affinity model predicts small-molecule druggability. Nature Biotechnology, 25, 71\u201375. https:\/\/doi.org\/10.1038\/nbt1273","journal-title":"Nature Biotechnology"},{"key":"10185_CR5","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.copbio.2018.01.025","volume":"53","author":"P Vormittag","year":"2018","unstructured":"Vormittag, P., Gunn, R., Ghorashian, S., & Veraitch, F. S. (2018). A guide to manufacturing CAR T cell therapies. Current Opinion in Biotechnology, 53, 164\u2013181. https:\/\/doi.org\/10.1016\/j.copbio.2018.01.025","journal-title":"Current Opinion in Biotechnology"},{"key":"10185_CR6","doi-asserted-by":"publisher","first-page":"876339","DOI":"10.3389\/fimmu.2022.876339","volume":"13","author":"N Watanabe","year":"2022","unstructured":"Watanabe, N., Mo, F., & McKenna, M. K. (2022). Impact of manufacturing procedures on CAR T cell functionality. Frontiers in Immunology, 13, 876339. https:\/\/doi.org\/10.3389\/fimmu.2022.876339","journal-title":"Frontiers in Immunology"},{"key":"10185_CR7","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1158\/2643-3230.Bcd-21-0084","volume":"2","author":"M Abou-El-Enein","year":"2021","unstructured":"Abou-El-Enein, M., et al. (2021). Scalable manufacturing of CAR T cells for cancer immunotherapy. Blood Cancer Discovery, 2, 408\u2013422. https:\/\/doi.org\/10.1158\/2643-3230.Bcd-21-0084","journal-title":"Blood Cancer Discovery"},{"key":"10185_CR8","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1111\/trf.14003","volume":"57","author":"ES Allen","year":"2017","unstructured":"Allen, E. S., et al. (2017). Autologous lymphapheresis for the production of chimeric antigen receptor T cells. Transfusion, 57, 1133\u20131141. https:\/\/doi.org\/10.1111\/trf.14003","journal-title":"Transfusion"},{"key":"10185_CR9","doi-asserted-by":"publisher","first-page":"100638","DOI":"10.1016\/j.ctarc.2022.100638","volume":"33","author":"W Sun","year":"2022","unstructured":"Sun, W., Jiang, Z., Jiang, W., & Yang, R. (2022). Universal chimeric antigen receptor T cell therapy - The future of cell therapy: A review providing clinical evidence. Cancer Treatment and Research Communications, 33, 100638. https:\/\/doi.org\/10.1016\/j.ctarc.2022.100638","journal-title":"Cancer Treatment and Research Communications"},{"key":"10185_CR10","doi-asserted-by":"publisher","first-page":"5697","DOI":"10.1182\/blood-2012-01-405365","volume":"119","author":"H Torikai","year":"2012","unstructured":"Torikai, H., et al. (2012). A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR. Blood, 119, 5697\u20135705. https:\/\/doi.org\/10.1182\/blood-2012-01-405365","journal-title":"Blood"},{"key":"10185_CR11","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","volume":"368","author":"SA Grupp","year":"2013","unstructured":"Grupp, S. A., et al. (2013). Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. The New England Journal of Medicine, 368, 1509\u20131518. https:\/\/doi.org\/10.1056\/NEJMoa1215134","journal-title":"The New England Journal of Medicine"},{"key":"10185_CR12","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.1182\/blood-2011-10-384388","volume":"119","author":"JN Kochenderfer","year":"2012","unstructured":"Kochenderfer, J. N., et al. (2012). B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood, 119, 2709\u20132720. https:\/\/doi.org\/10.1182\/blood-2011-10-384388","journal-title":"Blood"},{"key":"10185_CR13","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1038\/mt.2013.17","volume":"21","author":"CH Lamers","year":"2013","unstructured":"Lamers, C. H., et al. (2013). Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: Clinical evaluation and management of on-target toxicity. Molecular therapy\u202f: The journal of the American Society of Gene Therapy, 21, 904\u2013912. https:\/\/doi.org\/10.1038\/mt.2013.17","journal-title":"Molecular therapy : The journal of the American Society of Gene Therapy"},{"key":"10185_CR14","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1097\/mop.0000000000000043","volume":"26","author":"DM Barrett","year":"2014","unstructured":"Barrett, D. M., Teachey, D. T., & Grupp, S. A. (2014). Toxicity management for patients receiving novel T-cell engaging therapies. Current Opinion in Pediatrics, 26, 43\u201349. https:\/\/doi.org\/10.1097\/mop.0000000000000043","journal-title":"Current Opinion in Pediatrics"},{"key":"10185_CR15","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1126\/science.abq0225","volume":"378","author":"KG Daniels","year":"2022","unstructured":"Daniels, K. G., et al. (2022). Decoding CAR T cell phenotype using combinatorial signaling motif libraries and machine learning. Science (New York, N.Y.).=, 378, 1194\u20131200. https:\/\/doi.org\/10.1126\/science.abq0225","journal-title":"Science (New York, N.Y.).="},{"key":"10185_CR16","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1158\/2326-6066.Cir-18-0466","volume":"7","author":"D Alizadeh","year":"2019","unstructured":"Alizadeh, D., et al. (2019). IL15 Enhances CAR-T cell antitumor activity by reducing mTORC1 activity and preserving their stem cell memory phenotype. Cancer Immunology Research, 7, 759\u2013772. https:\/\/doi.org\/10.1158\/2326-6066.Cir-18-0466","journal-title":"Cancer Immunology Research"},{"key":"10185_CR17","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1038\/s41571-022-00607-3","volume":"19","author":"L Amini","year":"2022","unstructured":"Amini, L., et al. (2022). Preparing for CAR T cell therapy: Patient selection, bridging therapies and lymphodepletion. Nature Reviews. Clinical Oncology, 19, 342\u2013355. https:\/\/doi.org\/10.1038\/s41571-022-00607-3","journal-title":"Nature Reviews. Clinical Oncology"},{"key":"10185_CR18","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1146\/annurev.immunol.21.120601.141110","volume":"21","author":"RH Schwartz","year":"2003","unstructured":"Schwartz, R. H. (2003). T cell anergy. Annual Review of Immunology, 21, 305\u2013334. https:\/\/doi.org\/10.1146\/annurev.immunol.21.120601.141110","journal-title":"Annual Review of Immunology"},{"key":"10185_CR19","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1089\/hum.2011.058","volume":"22","author":"B Dropuli\u0107","year":"2011","unstructured":"Dropuli\u0107, B. (2011). Lentiviral vectors: Their molecular design, safety, and use in laboratory and preclinical research. Human Gene Therapy, 22, 649\u2013657. https:\/\/doi.org\/10.1089\/hum.2011.058","journal-title":"Human Gene Therapy"},{"key":"10185_CR20","doi-asserted-by":"publisher","first-page":"4334","DOI":"10.1182\/blood-2012-02-412973","volume":"120","author":"Q Zhou","year":"2012","unstructured":"Zhou, Q., et al. (2012). T-cell receptor gene transfer exclusively to human CD8(+) cells enhances tumor cell killing. Blood, 120, 4334\u20134342. https:\/\/doi.org\/10.1182\/blood-2012-02-412973","journal-title":"Blood"},{"key":"10185_CR21","doi-asserted-by":"publisher","unstructured":"Zhou, Q.,\u00a0et al. (2015). Exclusive transduction of human CD4+ T cells upon systemic delivery of CD4-targeted lentiviral vectors. Journal of immunology (Baltimore, Md. : 1950), 195, 2493\u20132501, https:\/\/doi.org\/10.4049\/jimmunol.1500956","DOI":"10.4049\/jimmunol.1500956"},{"key":"10185_CR22","doi-asserted-by":"publisher","unstructured":"Pfeiffer, A., et al. (2018). In vivo generation of human CD19-CAR T cells results in B-cell depletion and signs of cytokine release syndrome. EMBO Molecular Medicine, 10.\u00a0https:\/\/doi.org\/10.15252\/emmm.201809158","DOI":"10.15252\/emmm.201809158"},{"key":"10185_CR23","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.omtm.2022.06.004","volume":"26","author":"N Ho","year":"2022","unstructured":"Ho, N., et al. (2022). In vivo generation of CAR T cells in the presence of human myeloid cells. Molecular therapy. Methods & Clinical Development, 26, 144\u2013156. https:\/\/doi.org\/10.1016\/j.omtm.2022.06.004","journal-title":"Molecular therapy. Methods & clinical development"},{"key":"10185_CR24","doi-asserted-by":"publisher","first-page":"e1900286","DOI":"10.1002\/biot.201900286","volume":"15","author":"PD Mo\u00e7o","year":"2020","unstructured":"Mo\u00e7o, P. D., Aharony, N., & Kamen, A. (2020). Adeno-associated viral vectors for homology-directed generation of CAR-T cells. Biotechnology Journal, 15, e1900286. https:\/\/doi.org\/10.1002\/biot.201900286","journal-title":"Biotechnology Journal"},{"key":"10185_CR25","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.ymthe.2006.05.009","volume":"14","author":"Z Wu","year":"2006","unstructured":"Wu, Z., Asokan, A., & Samulski, R. J. (2006). Adeno-associated virus serotypes: Vector toolkit for human gene therapy. Molecular Therapy\u202f: The Journal of the American Society of Gene Therapy, 14, 316\u2013327. https:\/\/doi.org\/10.1016\/j.ymthe.2006.05.009","journal-title":"Molecular therapy : The journal of the American Society of Gene Therapy"},{"key":"10185_CR26","doi-asserted-by":"publisher","first-page":"e30","DOI":"10.1093\/nar\/gkv1121","volume":"44","author":"J Wang","year":"2016","unstructured":"Wang, J., et al. (2016). Highly efficient homology-driven genome editing in human T cells by combining zinc-finger nuclease mRNA and AAV6 donor delivery. Nucleic Acids Research, 44, e30. https:\/\/doi.org\/10.1093\/nar\/gkv1121","journal-title":"Nucleic acids research"},{"key":"10185_CR27","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/j.ymthe.2017.02.005","volume":"25","author":"DT MacLeod","year":"2017","unstructured":"MacLeod, D. T., et al. (2017). Integration of a CD19 CAR into the TCR alpha chain locus streamlines production of allogeneic gene-edited CAR T cells. Molecular Therapy: The Journal of the American Society of Gene Therapy, 25, 949\u2013961. https:\/\/doi.org\/10.1016\/j.ymthe.2017.02.005","journal-title":"Molecular therapy : The journal of the American Society of Gene Therapy"},{"key":"10185_CR28","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/s41592-019-0329-7","volume":"16","author":"X Dai","year":"2019","unstructured":"Dai, X., et al. (2019). One-step generation of modular CAR-T cells with AAV-Cpf1. Nature Methods, 16, 247\u2013254. https:\/\/doi.org\/10.1038\/s41592-019-0329-7","journal-title":"Nature methods"},{"key":"10185_CR29","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/s41408-021-00508-1","volume":"11","author":"W Nawaz","year":"2021","unstructured":"Nawaz, W., et al. (2021). AAV-mediated in vivo CAR gene therapy for targeting human T-cell leukemia. Blood Cancer Journal, 11, 119. https:\/\/doi.org\/10.1038\/s41408-021-00508-1","journal-title":"Blood cancer journal"},{"key":"10185_CR30","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1111\/imr.12478","volume":"275","author":"JM Brady","year":"2017","unstructured":"Brady, J. M., Baltimore, D., & Balazs, A. B. (2017). Antibody gene transfer with adeno-associated viral vectors as a method for HIV prevention. Immunological Reviews, 275, 324\u2013333. https:\/\/doi.org\/10.1111\/imr.12478","journal-title":"Immunological reviews"},{"key":"10185_CR31","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.cell.2022.12.022","volume":"186","author":"WA Nyberg","year":"2023","unstructured":"Nyberg, W. A., et al. (2023). An evolved AAV variant enables efficient genetic engineering of murine T cells. Cell, 186, 446\u2013460.e419. https:\/\/doi.org\/10.1016\/j.cell.2022.12.022","journal-title":"Cell"},{"key":"10185_CR32","doi-asserted-by":"publisher","first-page":"e1671761","DOI":"10.1080\/2162402x.2019.1671761","volume":"8","author":"S Agarwal","year":"2019","unstructured":"Agarwal, S., Weidner, T., Thalheimer, F. B., & Buchholz, C. J. (2019). In vivo generated human CAR T cells eradicate tumor cells. Oncoimmunology, 8, e1671761. https:\/\/doi.org\/10.1080\/2162402x.2019.1671761","journal-title":"Oncoimmunology"},{"key":"10185_CR33","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1016\/j.ymthe.2020.05.005","volume":"28","author":"S Agarwal","year":"2020","unstructured":"Agarwal, S., et al. (2020). In vivo generation of CAR T cells selectively in human CD4(+) lymphocytes. Molecular therapy\u202f: The Journal of the American Society of Gene Therapy, 28, 1783\u20131794. https:\/\/doi.org\/10.1016\/j.ymthe.2020.05.005","journal-title":"Molecular therapy : The journal of the American Society of Gene Therapy"},{"key":"10185_CR34","doi-asserted-by":"publisher","first-page":"5702","DOI":"10.1182\/bloodadvances.2020002229","volume":"4","author":"AM Frank","year":"2020","unstructured":"Frank, A. M., et al. (2020). Combining T-cell-specific activation and in vivo gene delivery through CD3-targeted lentiviral vectors. Blood Advances, 4, 5702\u20135715. https:\/\/doi.org\/10.1182\/bloodadvances.2020002229","journal-title":"Blood Advances"},{"key":"10185_CR35","doi-asserted-by":"publisher","unstructured":"Huckaby, J. T., et al. (2021). Bispecific binder redirected lentiviral vector enables in vivo engineering of CAR-T cells. Journal for Immunotherapy of Cancer, 9.\u00a0https:\/\/doi.org\/10.1136\/jitc-2021-002737","DOI":"10.1136\/jitc-2021-002737"},{"key":"10185_CR36","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1039\/d2nr05868e","volume":"15","author":"D Mathur","year":"2023","unstructured":"Mathur, D., Galvan, A. R., Green, C. M., Liu, K., & Medintz, I. L. (2023). Uptake and stability of DNA nanostructures in cells: A cross-sectional overview of the current state of the art. Nanoscale, 15, 2516\u20132528. https:\/\/doi.org\/10.1039\/d2nr05868e","journal-title":"Nanoscale"},{"key":"10185_CR37","doi-asserted-by":"publisher","unstructured":"Tian, R., Shang, Y., Wang, Y., Jiang, Q. & Ding, B. (2023) DNA nanomaterials-based platforms for cancer immunotherapy. Small Methods, e2201518.\u00a0https:\/\/doi.org\/10.1002\/smtd.202201518","DOI":"10.1002\/smtd.202201518"},{"key":"10185_CR38","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1038\/nnano.2017.57","volume":"12","author":"TT Smith","year":"2017","unstructured":"Smith, T. T., et al. (2017). In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers. Nature Nanotechnology, 12, 813\u2013820. https:\/\/doi.org\/10.1038\/nnano.2017.57","journal-title":"Nature nanotechnology"},{"key":"10185_CR39","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.abm0594","volume":"375","author":"JG Rurik","year":"2022","unstructured":"Rurik, J. G., et al. (2022). CAR T cells produced in vivo to treat cardiac injury. Science (New York, N.Y.), 375, 91\u201396. https:\/\/doi.org\/10.1126\/science.abm0594","journal-title":"Science (New York, N.Y.)"},{"key":"10185_CR40","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.scib.2023.11.055","volume":"69","author":"G Zhao","year":"2024","unstructured":"Zhao, G., Zhang, Y., Xu, C. F., & Wang, J. (2024). In vivo production of CAR-T cells using virus-mimetic fusogenic nanovesicles. Science Bulletin, 69, 354\u2013366. https:\/\/doi.org\/10.1016\/j.scib.2023.11.055","journal-title":"Science bulletin"},{"key":"10185_CR41","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/nri778","volume":"2","author":"SM Kaech","year":"2002","unstructured":"Kaech, S. M., Wherry, E. J., & Ahmed, R. (2002). Effector and memory T-cell differentiation: Implications for vaccine development. Nature Reviews. Immunology, 2, 251\u2013262. https:\/\/doi.org\/10.1038\/nri778","journal-title":"Nature reviews. Immunology"},{"key":"10185_CR42","doi-asserted-by":"publisher","unstructured":"Ok\u0142a, K., Farber, D. L. & Zou, W.\u00a0(2021). Tissue-resident memory T cells in tumor immunity and immunotherapy. The Journal of Experimental Medicine, 218.\u00a0https:\/\/doi.org\/10.1084\/jem.20201605","DOI":"10.1084\/jem.20201605"},{"key":"10185_CR43","doi-asserted-by":"publisher","unstructured":"Klebanoff, C. A., Gattinoni, L., & Restifo, N. P. (2012) Sorting through subsets: Which T-cell populations mediate highly effective adoptive immunotherapy? Journal of Immunotherapy (Hagerstown, Md. : 1997), 35, 651\u2013660.\u00a0https:\/\/doi.org\/10.1097\/CJI.0b013e31827806e6","DOI":"10.1097\/CJI.0b013e31827806e6"},{"key":"10185_CR44","doi-asserted-by":"publisher","first-page":"17469","DOI":"10.1073\/pnas.0907448106","volume":"106","author":"CS Hinrichs","year":"2009","unstructured":"Hinrichs, C. S., et al. (2009). Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunity. Proceedings of the National Academy of Sciences of the United States of America, 106, 17469\u201317474. https:\/\/doi.org\/10.1073\/pnas.0907448106","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10185_CR45","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1158\/1078-0432.Ccr-22-3232","volume":"29","author":"E El Marabti","year":"2023","unstructured":"El Marabti, E., & Abdel-Wahab, O. (2023). Enhancing CD19 chimeric antigen receptor T cells through memory-enriched T cells. Clinical Cancer Research\u202f: An official Journal of the American Association for Cancer Research, 29, 694\u2013696. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-22-3232","journal-title":"Clinical cancer research : An official Journal of the American Association for Cancer Research"},{"key":"10185_CR46","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1158\/2326-6066.Cir-17-0405","volume":"6","author":"S Ghassemi","year":"2018","unstructured":"Ghassemi, S., et al. (2018). Reducing ex vivo culture improves the antileukemic activity of chimeric antigen receptor (CAR) T cells. Cancer Immunology Research, 6, 1100\u20131109. https:\/\/doi.org\/10.1158\/2326-6066.Cir-17-0405","journal-title":"Cancer Immunology Research"},{"key":"10185_CR47","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1038\/s41587-022-01245-x","volume":"40","author":"P Agarwalla","year":"2022","unstructured":"Agarwalla, P., et al. (2022). Bioinstructive implantable scaffolds for rapid in vivo manufacture and release of CAR-T cells. Nature Biotechnology, 40, 1250\u20131258. https:\/\/doi.org\/10.1038\/s41587-022-01245-x","journal-title":"Nature Biotechnology"},{"key":"10185_CR48","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41408-022-00694-6","volume":"12","author":"J Yang","year":"2022","unstructured":"Yang, J., et al. (2022). Next-day manufacture of a novel anti-CD19 CAR-T therapy for B-cell acute lymphoblastic leukemia: First-in-human clinical study. Blood Cancer Journal, 12, 104. https:\/\/doi.org\/10.1038\/s41408-022-00694-6","journal-title":"Blood Cancer Journal"},{"key":"10185_CR49","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/s41408-022-00688-4","volume":"12","author":"C Zhang","year":"2022","unstructured":"Zhang, C., et al. (2022). Novel CD19 chimeric antigen receptor T cells manufactured next-day for acute lymphoblastic leukemia. Blood Cancer Journal, 12, 96. https:\/\/doi.org\/10.1038\/s41408-022-00688-4","journal-title":"Blood cancer journal"},{"key":"10185_CR50","doi-asserted-by":"publisher","unstructured":"Wang, Y. L. et al. (2021). Web-based quantitative structure-activity relationship resources facilitate effective drug discovery. Topics in Current Chemistry (Cham), 379, 37.\u00a0https:\/\/doi.org\/10.1007\/s41061-021-00349-3","DOI":"10.1007\/s41061-021-00349-3"},{"key":"10185_CR51","doi-asserted-by":"publisher","first-page":"5015","DOI":"10.1021\/acs.jmedchem.7b00389","volume":"60","author":"H Neelakantan","year":"2017","unstructured":"Neelakantan, H., et al. (2017). Structure-activity relationship for small molecule inhibitors of nicotinamide N-methyltransferase. Journal of Medicinal Chemistry, 60, 5015\u20135028. https:\/\/doi.org\/10.1021\/acs.jmedchem.7b00389","journal-title":"Journal of medicinal chemistry"},{"key":"10185_CR52","doi-asserted-by":"publisher","first-page":"e1900129","DOI":"10.1002\/ardp.201900129","volume":"352","author":"S Ding","year":"2019","unstructured":"Ding, S., et al. (2019). Exploration of the structure-activity relationship and druggability of novel oxazolidinone-based compounds as Gram-negative antibacterial agents. Archiv der Pharmazie, 352, e1900129. https:\/\/doi.org\/10.1002\/ardp.201900129","journal-title":"Archiv der Pharmazie"},{"key":"10185_CR53","doi-asserted-by":"publisher","first-page":"7770","DOI":"10.1021\/jm501045e","volume":"57","author":"T Xue","year":"2014","unstructured":"Xue, T., et al. (2014). Design, synthesis, and structure-activity and structure-pharmacokinetic relationship studies of novel [6,6,5] tricyclic fused oxazolidinones leading to the discovery of a potent, selective, and orally bioavailable FXa inhibitor. Journal of Medicinal Chemistry, 57, 7770\u20137791. https:\/\/doi.org\/10.1021\/jm501045e","journal-title":"Journal of Medicinal Chemistry"},{"key":"10185_CR54","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1186\/s12943-022-01663-0","volume":"21","author":"J Lu","year":"2022","unstructured":"Lu, J., & Jiang, G. (2022). The journey of CAR-T therapy in hematological malignancies. Molecular Cancer, 21, 194. https:\/\/doi.org\/10.1186\/s12943-022-01663-0","journal-title":"Molecular Cancer"},{"key":"10185_CR55","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s12943-022-01559-z","volume":"21","author":"A Dimitri","year":"2022","unstructured":"Dimitri, A., Herbst, F., & Fraietta, J. A. (2022). Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing. Molecular Cancer, 21, 78. https:\/\/doi.org\/10.1186\/s12943-022-01559-z","journal-title":"Molecular Cancer"},{"key":"10185_CR56","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.3389\/fimmu.2020.01965","volume":"11","author":"MA Morgan","year":"2020","unstructured":"Morgan, M. A., B\u00fcning, H., Sauer, M., & Schambach, A. (2020). Use of cell and genome modification technologies to generate improved \u201cOff-the-Shelf\u201d CAR T and CAR NK Cells. Frontiers in Immunology, 11, 1965. https:\/\/doi.org\/10.3389\/fimmu.2020.01965","journal-title":"Frontiers in Immunology"},{"key":"10185_CR57","doi-asserted-by":"publisher","unstructured":"Roselli, E.,\u00a0et al. (2021). 4\u20131BB and optimized CD28 co-stimulation enhances function of human mono-specific and bi-specific third-generation CAR T cells. Journal for Immunotherapy of Cancer, 9.\u00a0https:\/\/doi.org\/10.1136\/jitc-2021-003354","DOI":"10.1136\/jitc-2021-003354"},{"key":"10185_CR58","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1056\/NEJMoa1103849","volume":"365","author":"DL Porter","year":"2011","unstructured":"Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011). Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. The New England Journal of Medicine, 365, 725\u2013733. https:\/\/doi.org\/10.1056\/NEJMoa1103849","journal-title":"The New England journal of medicine"},{"key":"10185_CR59","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41571-022-00704-3","volume":"20","author":"CL Flugel","year":"2023","unstructured":"Flugel, C. L., et al. (2023). Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours. Nature Reviews. Clinical Oncology, 20, 49\u201362. https:\/\/doi.org\/10.1038\/s41571-022-00704-3","journal-title":"Nature reviews. Clinical oncology"},{"key":"10185_CR60","doi-asserted-by":"publisher","unstructured":"Shanmugasundaram, U.,\u00a0et al. (2020). Pulmonary Mycobacterium tuberculosis control associates with CXCR3- and CCR6-expressing antigen-specific Th1 and Th17 cell recruitment. JCI Insight, 5.\u00a0https:\/\/doi.org\/10.1172\/jci.insight.137858","DOI":"10.1172\/jci.insight.137858"},{"key":"10185_CR61","doi-asserted-by":"publisher","unstructured":"Mestermann, K., et al. (2019). The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on\/off switch for CAR T cells. Science Translational Medicine, 11.\u00a0https:\/\/doi.org\/10.1126\/scitranslmed.aau5907","DOI":"10.1126\/scitranslmed.aau5907"},{"key":"10185_CR62","doi-asserted-by":"publisher","unstructured":"Weber, E. W. et al. (2021). Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling. Science (New York, N.Y.), 372.\u00a0https:\/\/doi.org\/10.1126\/science.aba1786","DOI":"10.1126\/science.aba1786"},{"key":"10185_CR63","doi-asserted-by":"publisher","unstructured":"Preman, N. K., Barki, R. R., Vijayan, A., Sanjeeva, S. G. & Johnson, R. P. (2020). Recent developments in stimuli-responsive polymer nanogels for drug delivery and diagnostics: A review. European Journal of Pharmaceutics and Biopharmaceutics: Official Journal of Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik E.V., 157, 121\u2013153.\u00a0https:\/\/doi.org\/10.1016\/j.ejpb.2020.10.009","DOI":"10.1016\/j.ejpb.2020.10.009"},{"key":"10185_CR64","doi-asserted-by":"publisher","first-page":"6161","DOI":"10.1039\/c5cs00199d","volume":"44","author":"M Molina","year":"2015","unstructured":"Molina, M., et al. (2015). Stimuli-responsive nanogel composites and their application in nanomedicine. Chemical Society Reviews, 44, 6161\u20136186. https:\/\/doi.org\/10.1039\/c5cs00199d","journal-title":"Chemical Society Reviews"},{"key":"10185_CR65","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1038\/s41565-021-00982-5","volume":"16","author":"NT Nguyen","year":"2021","unstructured":"Nguyen, N. T., et al. (2021). Nano-optogenetic engineering of CAR T cells for precision immunotherapy with enhanced safety. Nature Nanotechnology, 16, 1424\u20131434. https:\/\/doi.org\/10.1038\/s41565-021-00982-5","journal-title":"Nature nanotechnology"},{"key":"10185_CR66","doi-asserted-by":"publisher","first-page":"eaay9209","DOI":"10.1126\/sciadv.aay9209","volume":"6","author":"Z Huang","year":"2020","unstructured":"Huang, Z., et al. (2020). Engineering light-controllable CAR T cells for cancer immunotherapy. Science Advances, 6, eaay9209. https:\/\/doi.org\/10.1126\/sciadv.aay9209","journal-title":"Science Advances"},{"key":"10185_CR67","unstructured":"Tsien, R. Y. (2003). Imagining imaging's future. Nature reviews. Molecular Cell Biology, Suppl, Ss16\u201321."},{"key":"10185_CR68","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1038\/s41551-021-00781-2","volume":"5","author":"IC Miller","year":"2021","unstructured":"Miller, I. C., et al. (2021). Enhanced intratumoural activity of CAR T cells engineered to produce immunomodulators under photothermal control. Nature Biomedical Engineering, 5, 1348\u20131359. https:\/\/doi.org\/10.1038\/s41551-021-00781-2","journal-title":"Nature Biomedical Engineering"},{"key":"10185_CR69","doi-asserted-by":"publisher","first-page":"e2007494","DOI":"10.1002\/smll.202007494","volume":"17","author":"Z Chen","year":"2021","unstructured":"Chen, Z., et al. (2021). Nanoengineered CAR-T biohybrids for solid tumor immunotherapy with microenvironment photothermal-remodeling strategy. Small (Weinheim an der Bergstrasse, Germany), 17, e2007494. https:\/\/doi.org\/10.1002\/smll.202007494","journal-title":"Small (Weinheim an der Bergstrasse, Germany)"},{"key":"10185_CR70","doi-asserted-by":"publisher","first-page":"616197","DOI":"10.1155\/2013\/616197","volume":"2013","author":"M Thanou","year":"2013","unstructured":"Thanou, M., & Gedroyc, W. (2013). MRI-guided focused ultrasound as a new method of drug delivery. Journal of Drug Delivery, 2013, 616197. https:\/\/doi.org\/10.1155\/2013\/616197","journal-title":"Journal of Drug Delivery"},{"key":"10185_CR71","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/nchembio.2233","volume":"13","author":"DI Piraner","year":"2017","unstructured":"Piraner, D. I., Abedi, M. H., Moser, B. A., Lee-Gosselin, A., & Shapiro, M. G. (2017). Tunable thermal bioswitches for in vivo control of microbial therapeutics. Nature Chemical Biology, 13, 75\u201380. https:\/\/doi.org\/10.1038\/nchembio.2233","journal-title":"Nature chemical biology"},{"key":"10185_CR72","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1111\/pbi.12659","volume":"15","author":"P Jacob","year":"2017","unstructured":"Jacob, P., Hirt, H., & Bendahmane, A. (2017). The heat-shock protein\/chaperone network and multiple stress resistance. Plant Biotechnology Journal, 15, 405\u2013414. https:\/\/doi.org\/10.1111\/pbi.12659","journal-title":"Plant biotechnology journal"},{"key":"10185_CR73","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1038\/s41551-021-00779-w","volume":"5","author":"Y Wu","year":"2021","unstructured":"Wu, Y., et al. (2021). Control of the activity of CAR-T cells within tumours via focused ultrasound. Nature Biomedical Engineering, 5, 1336\u20131347. https:\/\/doi.org\/10.1038\/s41551-021-00779-w","journal-title":"Nature biomedical engineering"},{"key":"10185_CR74","doi-asserted-by":"publisher","first-page":"4262","DOI":"10.1172\/jci84813","volume":"126","author":"PJ Paszkiewicz","year":"2016","unstructured":"Paszkiewicz, P. J., et al. (2016). Targeted antibody-mediated depletion of murine CD19 CAR T cells permanently reverses B cell aplasia. The Journal of Clinical Investigation, 126, 4262\u20134272. https:\/\/doi.org\/10.1172\/jci84813","journal-title":"The Journal of clinical investigation"},{"key":"10185_CR75","doi-asserted-by":"publisher","first-page":"104342","DOI":"10.1016\/j.cellimm.2021.104342","volume":"363","author":"Q Wang","year":"2021","unstructured":"Wang, Q., et al. (2021). A transgene-encoded truncated human epidermal growth factor receptor for depletion of anti- B-cell maturation antigen CAR-T cells. Cellular Immunology, 363, 104342. https:\/\/doi.org\/10.1016\/j.cellimm.2021.104342","journal-title":"Cellular immunology"},{"key":"10185_CR76","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1182\/blood-2014-01-545020","volume":"124","author":"B Philip","year":"2014","unstructured":"Philip, B., et al. (2014). A highly compact epitope-based marker\/suicide gene for easier and safer T-cell therapy. Blood, 124, 1277\u20131287. https:\/\/doi.org\/10.1182\/blood-2014-01-545020","journal-title":"Blood"},{"key":"10185_CR77","doi-asserted-by":"publisher","first-page":"235","DOI":"10.3389\/fphar.2014.00235","volume":"5","author":"T Gargett","year":"2014","unstructured":"Gargett, T., & Brown, M. P. (2014). The inducible caspase-9 suicide gene system as a \u201csafety switch\u201d to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells. Frontiers in Pharmacology, 5, 235. https:\/\/doi.org\/10.3389\/fphar.2014.00235","journal-title":"Frontiers in Pharmacology"},{"key":"10185_CR78","doi-asserted-by":"publisher","unstructured":"Guercio, M. et al. (2021). Inclusion of the inducible caspase 9 suicide gene in CAR construct increases safety of CAR.CD19 T cell therapy in B-cell malignancies. Frontiers in Immunology, 12, 755639.\u00a0https:\/\/doi.org\/10.3389\/fimmu.2021.755639","DOI":"10.3389\/fimmu.2021.755639"},{"key":"10185_CR79","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/j.ymthe.2017.01.011","volume":"25","author":"I Diaconu","year":"2017","unstructured":"Diaconu, I., et al. (2017). Inducible caspase-9 selectively modulates the toxicities of CD19-specific chimeric antigen receptor-modified T cells. Molecular therapy\u202f: The journal of the American Society of Gene Therapy, 25, 580\u2013592. https:\/\/doi.org\/10.1016\/j.ymthe.2017.01.011","journal-title":"Molecular therapy : The journal of the American Society of Gene Therapy"},{"key":"10185_CR80","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.cell.2016.09.011","volume":"167","author":"KT Roybal","year":"2016","unstructured":"Roybal, K. T., et al. (2016). Engineering T cells with customized therapeutic response programs using synthetic notch receptors. Cell, 167, 419-432.e416. https:\/\/doi.org\/10.1016\/j.cell.2016.09.011","journal-title":"Cell"},{"key":"10185_CR81","doi-asserted-by":"publisher","first-page":"9577","DOI":"10.1021\/acs.jmedchem.0c02054","volume":"64","author":"Y Zheng","year":"2021","unstructured":"Zheng, Y., Nandakumar, K. S., & Cheng, K. (2021). Optimization of CAR-T cell-based therapies using small-molecule-based safety switches. Journal of Medicinal Chemistry, 64, 9577\u20139591. https:\/\/doi.org\/10.1021\/acs.jmedchem.0c02054","journal-title":"Journal of medicinal chemistry"},{"key":"10185_CR82","doi-asserted-by":"publisher","first-page":"E450","DOI":"10.1073\/pnas.1524193113","volume":"113","author":"JS Ma","year":"2016","unstructured":"Ma, J. S., et al. (2016). Versatile strategy for controlling the specificity and activity of engineered T cells. Proceedings of the National Academy of Sciences of the United States of America, 113, E450-458. https:\/\/doi.org\/10.1073\/pnas.1524193113","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10185_CR83","doi-asserted-by":"publisher","unstructured":"Cao, Y., et al. (2016).Design of switchable chimeric antigen receptor T cells targeting breast cancer. Angewandte Chemie (International ed. in English), 55, 7520\u20137524. https:\/\/doi.org\/10.1002\/anie.201601902","DOI":"10.1002\/anie.201601902"},{"key":"10185_CR84","doi-asserted-by":"publisher","first-page":"2832","DOI":"10.1021\/jacs.5b00106","volume":"137","author":"MS Kim","year":"2015","unstructured":"Kim, M. S., et al. (2015). Redirection of genetically engineered CAR-T cells using bifunctional small molecules. Journal of the American Chemical Society, 137, 2832\u20132835. https:\/\/doi.org\/10.1021\/jacs.5b00106","journal-title":"Journal of the American Chemical Society"},{"key":"10185_CR85","doi-asserted-by":"publisher","first-page":"12178","DOI":"10.1002\/anie.202005432","volume":"59","author":"J Qi","year":"2020","unstructured":"Qi, J., et al. (2020). Chemically programmable and switchable CAR-T therapy. Angewandte Chemie (International ed in English), 59, 12178\u201312185. https:\/\/doi.org\/10.1002\/anie.202005432","journal-title":"Angewandte Chemie (International ed in English)"},{"key":"10185_CR86","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1126\/science.273.5272.239","volume":"273","author":"J Choi","year":"1996","unstructured":"Choi, J., Chen, J., Schreiber, S. L., & Clardy, J. (1996). Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP. Science (New York, N.Y.)., 273, 239\u2013242. https:\/\/doi.org\/10.1126\/science.273.5272.239","journal-title":"Science (New York, N.Y.)."},{"key":"10185_CR87","doi-asserted-by":"publisher","first-page":"aab4077","DOI":"10.1126\/science.aab4077","volume":"350","author":"CY Wu","year":"2015","unstructured":"Wu, C. Y., Roybal, K. T., Puchner, E. M., Onuffer, J., & Lim, W. A. (2015). Remote control of therapeutic T cells through a small molecule-gated chimeric receptor. Science (New York, N.Y.), 350, aab4077. https:\/\/doi.org\/10.1126\/science.aab4077","journal-title":"Science (New York, N.Y.)"},{"key":"10185_CR88","doi-asserted-by":"publisher","unstructured":"Leung, W. H.,\u00a0et al. (2019) Sensitive and adaptable pharmacological control of CAR T cells through extracellular receptor dimerization. JCI Insight, 5.\u00a0https:\/\/doi.org\/10.1172\/jci.insight.124430","DOI":"10.1172\/jci.insight.124430"},{"key":"10185_CR89","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.chembiol.2005.10.017","volume":"13","author":"JH Bayle","year":"2006","unstructured":"Bayle, J. H., et al. (2006). Rapamycin analogs with differential binding specificity permit orthogonal control of protein activity. Chemistry & Biology, 13, 99\u2013107. https:\/\/doi.org\/10.1016\/j.chembiol.2005.10.017","journal-title":"Chemistry & biology"},{"key":"10185_CR90","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.clim.2008.02.006","volume":"127","author":"S Blake","year":"2008","unstructured":"Blake, S., Hughes, T. P., Mayrhofer, G., & Lyons, A. B. (2008). The Src\/ABL kinase inhibitor dasatinib (BMS-354825) inhibits function of normal human T-lymphocytes in vitro. Clinical Immunology (Orlando, Fla.)., 127, 330\u2013339. https:\/\/doi.org\/10.1016\/j.clim.2008.02.006","journal-title":"Clinical Immunology (Orlando, Fla.)."},{"key":"10185_CR91","doi-asserted-by":"publisher","first-page":"eaba1624","DOI":"10.1126\/science.aba1624","volume":"378","author":"GM Allen","year":"2022","unstructured":"Allen, G. M., et al. (2022). Synthetic cytokine circuits that drive T cells into immune-excluded tumors. Science (New York, N.Y.), 378, eaba1624. https:\/\/doi.org\/10.1126\/science.aba1624","journal-title":"Science (New York, N.Y.)"},{"key":"10185_CR92","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1126\/science.add9665","volume":"378","author":"WA Lim","year":"2022","unstructured":"Lim, W. A. (2022). The emerging era of cell engineering: Harnessing the modularity of cells to program complex biological function. Science (New York N.Y.), 378, 848\u2013852. https:\/\/doi.org\/10.1126\/science.add9665","journal-title":"Science (New York N.Y.)"},{"key":"10185_CR93","doi-asserted-by":"publisher","first-page":"eabn8264","DOI":"10.1126\/sciadv.abn8264","volume":"8","author":"AK Grosskopf","year":"2022","unstructured":"Grosskopf, A. K., et al. (2022). Delivery of CAR-T cells in a transient injectable stimulatory hydrogel niche improves treatment of solid tumors. Science Advances, 8, eabn8264. https:\/\/doi.org\/10.1126\/sciadv.abn8264","journal-title":"Science Advances"},{"key":"10185_CR94","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/s41565-020-00813-z","volume":"16","author":"X Huang","year":"2021","unstructured":"Huang, X., et al. (2021). DNA scaffolds enable efficient and tunable functionalization of biomaterials for immune cell modulation. Nature Nanotechnology, 16, 214\u2013223. https:\/\/doi.org\/10.1038\/s41565-020-00813-z","journal-title":"Nature Nanotechnology"},{"key":"10185_CR95","doi-asserted-by":"publisher","first-page":"2625","DOI":"10.1182\/blood-2013-11-492231","volume":"123","author":"MV Maus","year":"2014","unstructured":"Maus, M. V., Grupp, S. A., Porter, D. L., & June, C. H. (2014). Antibody-modified T cells: CARs take the front seat for hematologic malignancies. Blood, 123, 2625\u20132635. https:\/\/doi.org\/10.1182\/blood-2013-11-492231","journal-title":"Blood"},{"key":"10185_CR96","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s41586-019-1054-1","volume":"568","author":"M Hamieh","year":"2019","unstructured":"Hamieh, M., et al. (2019). CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape. Nature, 568, 112\u2013116. https:\/\/doi.org\/10.1038\/s41586-019-1054-1","journal-title":"Nature"},{"key":"10185_CR97","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","volume":"11","author":"RC Sterner","year":"2021","unstructured":"Sterner, R. C., & Sterner, R. M. (2021). CAR-T cell therapy: Current limitations and potential strategies. Blood Cancer Journal, 11, 69. https:\/\/doi.org\/10.1038\/s41408-021-00459-7","journal-title":"Blood Cancer Journal"},{"key":"10185_CR98","doi-asserted-by":"publisher","first-page":"128","DOI":"10.3389\/fimmu.2019.00128","volume":"10","author":"M Martinez","year":"2019","unstructured":"Martinez, M., & Moon, E. K. (2019). CAR T cells for solid tumors: New strategies for finding, infiltrating, and surviving in the tumor microenvironment. Frontiers in Immunology, 10, 128. https:\/\/doi.org\/10.3389\/fimmu.2019.00128","journal-title":"Frontiers in Immunology"},{"key":"10185_CR99","doi-asserted-by":"publisher","first-page":"663201","DOI":"10.3389\/fimmu.2021.663201","volume":"12","author":"L Miao","year":"2021","unstructured":"Miao, L., Zhang, Z., Ren, Z., & Li, Y. (2021). Reactions related to CAR-T cell therapy. Frontiers in Immunology, 12, 663201. https:\/\/doi.org\/10.3389\/fimmu.2021.663201","journal-title":"Frontiers in Immunology"},{"key":"10185_CR100","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1093\/eurheartj\/ehac106","volume":"43","author":"M Totzeck","year":"2022","unstructured":"Totzeck, M., Michel, L., Lin, Y., Herrmann, J., & Rassaf, T. (2022). Cardiotoxicity from chimeric antigen receptor-T cell therapy for advanced malignancies. European Heart Journal, 43, 1928\u20131940. https:\/\/doi.org\/10.1093\/eurheartj\/ehac106","journal-title":"European heart journal"},{"key":"10185_CR101","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1172\/jci46110","volume":"121","author":"B Savoldo","year":"2011","unstructured":"Savoldo, B., et al. (2011). CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. The Journal of Clinical Investigation, 121, 1822\u20131826. https:\/\/doi.org\/10.1172\/jci46110","journal-title":"The Journal of Clinical Investigation"},{"key":"10185_CR102","doi-asserted-by":"publisher","first-page":"95ra73","DOI":"10.1126\/scitranslmed.3002842","volume":"3","author":"M Kalos","year":"2011","unstructured":"Kalos, M., et al. (2011). T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Science Translational Medicine, 3, 95ra73.","journal-title":"Science Translational Medicine"},{"key":"10185_CR103","doi-asserted-by":"publisher","first-page":"4133","DOI":"10.1182\/blood-2011-12-400044","volume":"119","author":"HJ Pegram","year":"2012","unstructured":"Pegram, H. J., et al. (2012). Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood, 119, 4133\u20134141. https:\/\/doi.org\/10.1182\/blood-2011-12-400044","journal-title":"Blood"},{"key":"10185_CR104","doi-asserted-by":"publisher","unstructured":"Choe, J. H. et al., (2021). SynNotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma. Science Translational Medicine, 13. https:\/\/doi.org\/10.1126\/scitranslmed.abe7378","DOI":"10.1126\/scitranslmed.abe7378"},{"key":"10185_CR105","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.stem.2022.02.009","volume":"29","author":"Z Wang","year":"2022","unstructured":"Wang, Z., et al. (2022). 3D-organoid culture supports differentiation of human CAR(+) iPSCs into highly functional CAR T cells. Cell Stem Cell, 29, 515-527.e518. https:\/\/doi.org\/10.1016\/j.stem.2022.02.009","journal-title":"Cell Stem Cell"},{"key":"10185_CR106","doi-asserted-by":"publisher","first-page":"878209","DOI":"10.3389\/fimmu.2022.878209","volume":"13","author":"G L\u00f3pez-Cantillo","year":"2022","unstructured":"L\u00f3pez-Cantillo, G., Urue\u00f1a, C., Camacho, B. A., & Ram\u00edrez-Segura, C. (2022). CAR-T cell performance: How to improve their persistence? Frontiers in Immunology, 13, 878209. https:\/\/doi.org\/10.3389\/fimmu.2022.878209","journal-title":"Frontiers in Immunology"},{"key":"10185_CR107","doi-asserted-by":"publisher","first-page":"1101769","DOI":"10.3389\/fimmu.2023.1101769","volume":"14","author":"K Zhao","year":"2023","unstructured":"Zhao, K., et al. (2023). The altering cellular components and function in tumor microenvironment during remissive and relapsed stages of anti-CD19 CAR T-cell treated lymphoma mice. Frontiers in Immunology, 14, 1101769. https:\/\/doi.org\/10.3389\/fimmu.2023.1101769","journal-title":"Frontiers in Immunology"},{"key":"10185_CR108","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s13045-018-0629-x","volume":"11","author":"D Kasakovski","year":"2018","unstructured":"Kasakovski, D., Xu, L., & Li, Y. (2018). T cell senescence and CAR-T cell exhaustion in hematological malignancies. Journal of Hematology & Oncology, 11, 91. https:\/\/doi.org\/10.1186\/s13045-018-0629-x","journal-title":"Journal of Hematology & Oncology"},{"key":"10185_CR109","doi-asserted-by":"publisher","first-page":"e202113341","DOI":"10.1002\/anie.202113341","volume":"61","author":"JV Napoleon","year":"2022","unstructured":"Napoleon, J. V., Zhang, B., Luo, Q., Srinivasarao, M., & Low, P. S. (2022). Design, synthesis, and targeted delivery of an immune stimulant that selectively reactivates exhausted CAR T cells. Angewandte Chemie (International ed. in English), 61, e202113341. https:\/\/doi.org\/10.1002\/anie.202113341","journal-title":"Angewandte Chemie (International ed. in English)"},{"key":"10185_CR110","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1016\/j.ccell.2021.05.011","volume":"39","author":"CC Zebley","year":"2021","unstructured":"Zebley, C. C., & Youngblood, B. (2021). CAR T cells need a pitstop to win the race. Cancer Cell, 39, 756\u2013758. https:\/\/doi.org\/10.1016\/j.ccell.2021.05.011","journal-title":"Cancer Cell"},{"key":"10185_CR111","doi-asserted-by":"publisher","unstructured":"Tantalo, D. G., et al. (2021). Understanding T cell phenotype for the design of effective chimeric antigen receptor T cell therapies. Journal ForImmunotherapy of Cancer, 9.\u00a0https:\/\/doi.org\/10.1136\/jitc-2021-002555","DOI":"10.1136\/jitc-2021-002555"},{"key":"10185_CR112","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1038\/s41586-022-05626-9","volume":"614","author":"AG Soerens","year":"2023","unstructured":"Soerens, A. G., et al. (2023). Functional T cells are capable of supernumerary cell division and longevity. Nature, 614, 762\u2013766. https:\/\/doi.org\/10.1038\/s41586-022-05626-9","journal-title":"Nature"}],"container-title":["Cancer and Metastasis Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10555-024-10185-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10555-024-10185-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10555-024-10185-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T08:11:28Z","timestamp":1722845488000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10555-024-10185-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,9]]},"references-count":112,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["10185"],"URL":"https:\/\/doi.org\/10.1007\/s10555-024-10185-8","relation":{},"ISSN":["0167-7659","1573-7233"],"issn-type":[{"value":"0167-7659","type":"print"},{"value":"1573-7233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,9]]},"assertion":[{"value":"26 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}